PlantPharm Biomed’s objective is to become the leader in manufacturing of plant-grown vaccines within the next five years. The company employs gene-edited plants in lieu of traditional single cell fermentation systems to produce oral vaccines with significant competitive advantages over injected vaccines; including shelf-stable, oral dose forms avoiding cold-chain storage problems and hypodermic needles. Since the vaccine administration is oral rather than injected it is easier to administer and avoids shelf-life problems associated with liquid vaccines, particularly in countries with inadequate logistics. This means that the powerful oral dosage version of a vaccine can now be administered broadly in both developed and developing countries previously limited by local logistic barriers. PlantPharm Biomed’s Management Team are each experts in their respective fields of knowledge and proficient in optimizing the vaccine production capabilities of the oral vaccine platform.